Skip to main content
Premium Trial:

Request an Annual Quote

EMD Serono, Pfizer, Broad Institute to Genomically Profile Lupus Patients

NEW YORK (GenomeWeb News) – EMD Serono announced on Tuesday a research agreement with Pfizer and the Broad Institute to genomically profile systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients.

As part of the project, being funded jointly by EMD Serono and Pfizer, the Broad will use biochemical and next-generation sequencing technologies to investigate samples from SLE and LN patients, as well as analyze immune cell subpopulations, in order to identify biomarkers to better define patient populations for future therapies.

Through computational approaches, the researchers also aim to identify molecular drivers of SLE and LN kidney flares in the hopes of discovering potential novel drug targets that can serve as the basis of new therapies, EMD Serono said.

EMD Serono and Pfizer will have real-time access to all data and analysis. Each will also be able to send a research scientist to the Broad "to foster [the] exchange of technology expertise" in computational and experimental genomic profiling.

Financial and other terms of the agreement were not disclosed.

"Technical advances now make it possible for us to sequence RNA in very small numbers of cells, enabling us to be more comprehensive in our analysis of cell types and states in lupus patients," Nir Hacohen, associate professor at Massachusetts General Hospital and Harvard Medical School, and senior associate member at the Broad, said in a statement. "We will collect millions of unbiased measurements from lupus patients over many time points along with key clinical variables. We will use this dataset to infer active biological pathways in these patients and develop novel dynamic models of lupus pathogenesis."

"Combined with the Broad Institute's technical know-how, we see this collaboration aiming for a significant contribution to potential future innovative treatments of lupus and lupus nephritis," Harsukh Parmar, head of the Translational Innovation Platform Immunology & Neurodegenerative Diseases at EMD Serono, added. "This is in line with our concept to integrate genomic profiling and system biology approaches throughout our preclinical and clinical programs."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.